+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bacterial Vaginosis - Pipeline Review, H2 2020

  • ID: 5137261
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 75 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Dare Bioscience Inc
  • Evofem Biosciences Inc
  • Melinta Therapeutics Inc
  • Next Science Ltd
  • Osel Inc
  • PhagoMed Biopharma GmbH
  • MORE
Bacterial Vaginosis - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Vaginosis - Pipeline Review, H2 2020, provides an overview of the Bacterial Vaginosis (Infectious Disease) pipeline landscape.

Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Bacterial Vaginosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 1, 5, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Dare Bioscience Inc
  • Evofem Biosciences Inc
  • Melinta Therapeutics Inc
  • Next Science Ltd
  • Osel Inc
  • PhagoMed Biopharma GmbH
  • MORE
  • Introduction
  • Report Coverage
  • Bacterial Vaginosis - Overview
  • Bacterial Vaginosis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Bacterial Vaginosis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Bacterial Vaginosis - Companies Involved in Therapeutics Development
  • Dare Bioscience Inc
  • Evofem Biosciences Inc
  • Hammock Pharmaceuticals Inc
  • Hennepin Life Sciences LLC
  • Melinta Therapeutics Inc
  • Next Science Ltd
  • Osel Inc
  • PhagoMed Biopharma GmbH
  • Pharmiva AB
  • Profem GmbH
  • Starpharma Holdings Ltd
  • Suzhou Ousai Weike Biomedical Technology Co Ltd
  • TenNor Therapeutics Ltd
  • Toltec Pharmaceuticals LLC
  • Bacterial Vaginosis - Drug Profiles
(citric acid + lactic acid + potassium bitartrate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • astodrimer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Biologic for Bacterial Vaginosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bacterial Vaginosis - Dormant Projects
  • Bacterial Vaginosis - Discontinued Products
  • Bacterial Vaginosis - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Bacterial Vaginosis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Bacterial Vaginosis - Pipeline by Dare Bioscience Inc, H2 2020
  • Bacterial Vaginosis - Pipeline by Evofem Biosciences Inc, H2 2020
  • Bacterial Vaginosis - Pipeline by Hammock Pharmaceuticals Inc, H2 2020
  • Bacterial Vaginosis - Pipeline by Hennepin Life Sciences LLC, H2 2020
  • Bacterial Vaginosis - Pipeline by Melinta Therapeutics Inc, H2 2020
  • Bacterial Vaginosis - Pipeline by Next Science Ltd, H2 2020
  • Bacterial Vaginosis - Pipeline by Osel Inc, H2 2020
  • Bacterial Vaginosis - Pipeline by PhagoMed Biopharma GmbH, H2 2020
  • Bacterial Vaginosis - Pipeline by Pharmiva AB, H2 2020
  • Bacterial Vaginosis - Pipeline by Profem GmbH, H2 2020
  • Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, H2 2020
  • Bacterial Vaginosis - Pipeline by Suzhou Ousai Weike Biomedical Technology Co Ltd, H2 2020
  • Bacterial Vaginosis - Pipeline by TenNor Therapeutics Ltd, H2 2020
  • Bacterial Vaginosis - Pipeline by Toltec Pharmaceuticals LLC, H2 2020
  • Bacterial Vaginosis - Dormant Projects, H2 2020
  • Bacterial Vaginosis - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Bacterial Vaginosis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • Dare Bioscience Inc
  • Evofem Biosciences Inc
  • Hammock Pharmaceuticals Inc
  • Hennepin Life Sciences LLC
  • Melinta Therapeutics Inc
  • Next Science Ltd
  • Osel Inc
  • PhagoMed Biopharma GmbH
  • Pharmiva AB
  • Profem GmbH
  • Starpharma Holdings Ltd
  • Suzhou Ousai Weike Biomedical Technology Co Ltd
  • TenNor Therapeutics Ltd
  • Toltec Pharmaceuticals LLC
Note: Product cover images may vary from those shown
Adroll
adroll